Uveitis in seronegative arthritis.
Uveitis is the most frequent extra-articular feature in seronegative arthritis and is part of the classification criteria for spondyloarthritis. Recent studies confirm a prevalence of up to one third of patients with spondyloarthritis and a relationship with HLA-B27 and disease duration. In recent forms of the disease, a relation with infectious episodes, inflammatory bowel disease, and cervical spine involvement has been reported. Many data argue for the implication of the IL23/IL17 pathway in uveitis, already obvious in spondyloarthritis. Studies with NSAIDs, DMARDs, and anti-TNF agents demonstrated the ability of these treatments to reduce the incidence of flares of uveitis in spondyloarthritis. Only a few data are available with other biologic agents. New onset of uveitis during anti-TNF therapy has been reported. The Il-17 blockade may be a new option for treating both uveitis and the underlying rheumatic condition.
Department of Rheumatology, University Teaching Hospital, and University of Franche-Comté, Besançon, France. dwendling@chu-besancon.fr
Daniel
D
Wendling
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001685:Biological Factors / Q000627:therapeutic use; D001688:Biological Products; D002986:Clinical Trials as Topic; D015796:HLA-B27 Antigen / Q000235:genetics; D006801:Humans; D007155:Immunologic Factors / Q000097:blood*; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D012217:Rheumatoid Factor / Q000097:blood*; D025241:Spondylarthritis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014605:Uveitis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000276:immunology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D001685:Biological Factors; D001688:Biological Products; D015796:HLA-B27 Antigen; D007155:Immunologic Factors; D020381:Interleukin-17; D014409:Tumor Necrosis Factor-alpha; D012217:Rheumatoid Factor